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Abstract
Objective: In idiopathic inflammatory myopathies (IIM) infiltration of immune cells into muscle and upregulation of MHC-I
expression implies increased antigen presentation and involvement of the proteasome system. To decipher the role of
immunoproteasomes in myositis, we investigated individual cell types and muscle tissues and focused on possible immune
triggers.
Methods: Expression of constitutive (PSMB5, -6, -7) and corresponding immunoproteasomal subunits (PSMB8, -9, -10) was
analyzed by real-time RT-PCR in muscle biopsies and sorted peripheral blood cells of patients with IIM, non-inflammatory
myopathies (NIM) and healthy donors (HD). Protein analysis in muscle biopsies was performed by western blot. Affymetrix
HG-U133 platform derived transcriptome data from biopsies of different muscle diseases and from immune cell types as
well as monocyte stimulation experiments were used for validation, coregulation and coexpression analyses.
Results: Real-time RT-PCR revealed significantly increased expression of immunoproteasomal subunits (PSMB8/-9/-10) in
DC, monocytes and CD8+ T-cells in IIM. In muscle biopsies, the immunosubunits were elevated in IIM compared to NIM and
exceeded levels of matched blood samples. Proteins of PSMB8 and -9 were found only in IIM but not NIM muscle biopsies.
Reanalysis of 78 myositis and 20 healthy muscle transcriptomes confirmed these results and revealed involvement of the
antigen processing and presentation pathway. Comparison with reference profiles of sorted immune cells and healthy
muscle confirmed upregulation of PSMB8 and -9 in myositis biopsies beyond infiltration related changes. This upregulation
correlated highest with STAT1, IRF1 and IFNc expression. Elevation of T-cell specific transcripts in active IIM muscles was
accompanied by increased expression of DC and monocyte marker genes and thus reflects the cell type specific
involvement observed in peripheral blood.
Conclusions: Immunoproteasomes seem to indicate IIM activity and suggest that dominant involvement of antigen
processing and presentation may qualify these diseases exemplarily for the evolving therapeutic concepts of
immunoproteasome specific inhibition.
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Introduction
Idiopathic inflammatory myopathies (IIM) are a heterogenous
group of muscle diseases characterized by inflammatory infiltrates
in the skeletal muscle. Three major diseases are defined:
dermatomyositis (DM), polymyositis (PM), and inclusion body
myositis (IBM). The main autoimmune response in DM resembles
a microangiopathy affecting skin and muscle tissue. In polymyo-
sitis and inclusion body myositis, cytotoxic CD8+ T cells invade
muscle fibers. All of the invaded fibers and numerous non-invaded
fibers express increased amounts of major histocompatibility
complex class I (MHC-I) molecules [1]. In fact, the presence of
MHC-I/CD8+ complex is considered as a characteristic immu-
nopathological marker of PM and IBM [2]. Continuous upregula-
tion of expression of MHC class I molecules in muscle fibers is
thought to induce an endoplasmic reticulum stress response with
accumulation of misfolded glycoproteins and activation of nuclear
factor kappa B (NF-kB). As a consequence, MHC-I/CD8+
complexes may form and perpetuate an autoinflammatory
response [3].
PLOS ONE | www.plosone.org 1 August 2014 | Volume 9 | Issue 8 | e104048
The ubiquitin-proteasome system (UPS) is a 26S, non-lysosom-
al, multicatalytic, and multisubunit complex involved in the
ubiquitin-dependent, selective intracellular degradation of proteins
[4]. In this way, the proteasome plays a central role in the
activation of transcription factors such as NF-kB [5]. Furthermore,
it is involved in the generation of peptides presented by the MHC-
I to the antigen receptors of cytotoxic T cells [6,7], and thus, is
involved in the regulation of the inflammatory response. Many
studies suggest that the proteasome participates in muscle fiber
degradation in various physiological and pathological conditions
and may therefore also play an important role in myositis [8,9].
The 26S proteasome is composed of a proteolytically active
core, namely the 20S proteasome, and one or two 19S regulator
complexes. The 20S or constitutive proteasome is a cylindrical
particle that consists of four rings, each composed of seven
different subunits. The outer two rings are formed by seven alpha-
type subunits (PSMA1–PSMA7), while the inner two rings contain
seven beta-type subunits (PSMB1–PSMB7) [6]. The proteolyti-
cally active sites are limited to three constitutive beta subunits,
proteasome subunit beta type 5-PSMB5, proteasome subunit beta
type 6-PSMB6 and proteasome subunit beta type 7-PSMB7.[10].
Importantly, under the influence of the pro-inflammatory cytokine
IFNc, the structure and the catalytic properties of the constitutive
proteasome are modified by substitution of the catalytic subunits
PSMB5, PSMB6 and PSMB7 with three catalytic immunosubu-
nits proteasome subunit beta type 8-PSMB8, proteasome subunit
beta type 9-PSMB9 and proteasome subunit beta type 10-
PSMB10 respectively, leading to the formation of the so-called
immunoproteasome. This process is considered to strongly
influence the production of peptides for antigen presentation by
MHC class I as well as the immune response [11–13]. As IFNc is
also secreted in IIM [14], the immunoproteasomal system may
also contribute to pathomechanisms in myositis. Recently,
mutations in human were detected in proteasome subunit PSMB8,
which cause joint contractures, muscle atrophy, microcytic
anemia, and panniculitis-induced lipodystrophy syndrome in
addition to other autoinflammatory syndromes [15–18]. Impaired
immunoproteasome assembly and decreased proteolytic activity
have been confirmed in some of these diseases. On the other hand,
elevated levels of circulating proteasomes as well as autoantibodies
against several proteasomal subunits have been detected in
patients with autoimmune myositis and other autoimmune
disorders [19,20]. Moreover, it has also been shown that anti-
proteasome autoantibodies derived from patients with connective
tissue diseases, including a patient with polymyositis, were capable
of blocking the stimulation of the catalytic proteasome core
complex by the proteasome activator PA28, consisting of the
subunits alpha (PSME1) and beta (PSME2) [21]. Additionally, an
upregulation of some proteasomal genes has been shown in
PBMCs of patients with systemic autoimmune disorders including
patients with PM [22].
Based on the existing but so far indirect assumption of an
involvement of the proteasome system in the pathogenesis of IIM,
we investigated the expression of all catalytic proteasome subunits
in inflammatory and non-inflammatory myopathies in order to
search for an activation of the 20S core complex in patients with
autoimmune myositis. Results were validated and comprehensive-
ly screened in a large panel of disease related as well as cell type
and stimulation specific transcriptome data sets in order to confirm
our results and to identify induction mechanisms and the
regulatory network for the immune proteasome subunits.
Materials and Methods
Ethics Statement
The study was performed in accordance with the 1964
Declaration of Helsinki and approved by the ‘‘Charité University
Medicine ethics committee I of Charité Campus Mitte’’ and
patients provided written consent to participate in the study.
Patients and healthy donors
Expression of proteasome subunits was investigated in 17
patients with idiopathic inflammatory myopathies (IIM), including
polymyositis (PM, n = 5), dermatomyositis (DM, n = 5), and
overlap-syndromes with myositis (OM, n = 7) (8 male, 9 female,
mean age 54.3 years, age range 22–72 years). Patients were
selected based on typical clinical symptoms, laboratory and/or
muscle biopsy findings, which were indicative for the different
groups of myopathies. Patients with PM and DM fulfilled the
classification criteria according to Bohan and Peter [23,24]. For
details of diagnosis and clinical parameters see supplementary
table S1. Autoantibody screening was performed according to
diagnostic standards including ANA in indirect immunofluores-
cence on HEp2 cells. Depending on the result of the ANA pattern,
further differentiation of the antibody reactivity was performed for
detection of ENA using ELISA. Furthermore, a profile of myositis
specific autoantibodies including anti-Jo1-, anti-SRP-, anti-Mi2,
anti-PM/Scl and anti-U1RNPantibodies as well as anti-proteaso-
mal antibodies was analyzed in each suspected case of myositis.
Controls included 7 patients with different non-inflammatory
myopathies (NIM, 4 male, 3 female, mean age 48.7 years, age
range 35–59 years). Time and patient matched samples of muscle
biopsies and blood were taken from 14 patients. Control samples
from 15 healthy donors (HD, 2 male, 13 female, mean age 45
years, age range 27–56 years without clinical signs of disease, no
clinical signs of muscular weakness, no medication) included only
blood and no muscle biopsies. All patients were diagnosed at the
Department of Rheumatology and Clinical Immunology, Charité
– University Medicine Berlin and informed consent was obtained
from all subjects.
Isolation of peripheral blood mononuclear cells (PBMCs)
and cellular subsets
PBMCs were collected by Ficoll density gradient centrifugation
(Biochrom, Germany) and divided into two fractions. One was
used for separation of dendritic cells (DCs) by Magnetic Cell
Separation (MACS) using the Blood Dendritic Cell Isolation Kit-II
(Miltenyi Biotec, Germany), the other for isolation of T
lymphocytes (CD4+, CD8+), B lymphocytes (CD19+), and
monocytes (CD14+) by fluorescence activated cell sorting (FACS)
with a FACS DiVa Flow Cytometer (BD, Germany).
Collection of muscle biopsies
Muscle tissues were stabilized in RNA later (Qiagen, Germany)
to avoid RNA degradation and were stored at 270uC. For RNA
isolation, biopsies were ground with a pestle and mortar in the
presence of liquid N2 to protect RNA against degradation.
Disrupted samples were then added to lysis buffer containing b-
mercaptoethanol.
RNA isolation, reverse transcription into cDNA and real-
time reverse transcriptase-polymerase chain reaction
(real time RT-PCR)
RNA was isolated from muscle tissues and blood cells using the
NucleoSpin RNA/Protein kit (Macherey-Nagel, Germany). First-
Immunoproteasomes in Myositis
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strand cDNA was synthesized using the SuperScript III First-
Strand Synthesis System for RT-PCR (Invitrogen, Germany)
according to the instructions of the manufacturer.
Forward and reverse primers of proteasome subunits PSMB5,
PSMB6, PSMB7, PSMB8, PSMB9 and PSMB10 for real time
RT-PCR were designed as described elsewhere [25].
Amplification reactions contained SYBR Green PCR Master
Mix (Applied Biosystems), 200 nM forward and reverse primers
for each gene and cDNA. Real-time PCR was performed in
triplicates using the ABI prism 5700 Sequence Detection System
(Applied Biosystems).
Relative expression of the target compared to the house keeping
gene beta-actin was determined as R~ E
CThouse { keeping { gene
ECTtarget { gene
[26],
with E representing the amplification efficiency of the respective
primer system. Mann-Whitney U-test was applied for group
comparisons (figures 1, 2, 3).
Western blot analysis
Muscle biopsies were minced in the presence of radioimmuno-
precipitation assay (RIPA) lysis buffer. PBMCs were used as
positive control and treated with the same lysis buffer. 30 mg of
total protein from tissue homogenate or cell lysate were loaded and
fractionated by 15% sodium dodecyl sulfate polyacrylamide gel
Figure 1. Expression of immunoproteasomal subunits in immune cells: Gene expression of immunoproteasomal subunits (PSMB8–10) in
CD4+, CD8+, CD19+, CD14+ and DCs of patients with myopathies (PM, DM, OM, NIM) and controls (HD). Data are shown as relative expression
normalized to beta actin. Box plots indicate percentiles 0, 25, 50, 75 and 100. Groups were compared by Mann-Whitney U test and statistical
significance is indicated for p,0.05 (*) and p,0.01 (**). Significantly higher expression of PSMB8 was observed in CD14+ cells and DC of PM patients
compared to HD or DM, NIM and HDs, respectively. PSMB9 was increased in CD8+ and CD14+ of DM and in DCs of PM and DM patients compared to
NIM. PSMB10 was found increased in PM patients compared to DM, NIM and HD in CD8+, compared to HD in CD19+ and CD14+ cells and compared
to OM, NIM, and HD in DCs.
doi:10.1371/journal.pone.0104048.g001
Immunoproteasomes in Myositis
PLOS ONE | www.plosone.org 3 August 2014 | Volume 9 | Issue 8 | e104048
Figure 2. Expression of catalytic proteasomal subunits in muscle: Gene expression analysis of constitutive and immunoproteasomal subunits
(PSMB5–10) in muscle biopsies of patients with inflammatory myopathies (IM) and patients with non inflammatory myopathies (NIM). Data are shown
as relative expression normalized to beta actin. Box plots indicate percentiles 0, 25, 50, 75 and 100. Groups were compared by Mann-Whitney U test
and statistical significance is indicated for p,0.05 (*), p,0.01 (**) and p,0.001 (***). Comparing to NIM, mean relative expression levels in IM
revealed 4-fold for PSMB8 [0.30260.139 and 0.07560.041] and about 5-fold increase for PSMB9 [0.04960.029 and 0.00960.002] but less than 2-fold
for PSMB10 [0.06560.064 and 0.03660.022].
doi:10.1371/journal.pone.0104048.g002
Figure 3. Comparison of immunoproteosomal subunit expression between paired samples from isolated cells and muscle tissue:
Gene expression analysis of immunoproteasomal subunits (PSMB8–10) in muscle biopsies vs. CD4+, CD8+, CD14+, CD19+, and DCs from patients with
inflammatory myopathies (IM) and patients with non-inflammatory myopathies (NIM). Data are shown as relative expression normalized to beta actin.
Box plots indicate percentiles 0, 25, 50, 75 and 100. Groups were compared by Mann-Whitney U test and statistical significance is indicated for p,
0.05 (*) and p,0.01 (**).
doi:10.1371/journal.pone.0104048.g003
Immunoproteasomes in Myositis
PLOS ONE | www.plosone.org 4 August 2014 | Volume 9 | Issue 8 | e104048
electrophoresis. After transfer to a polyvinylidene fluoride (PVDF)
membrane, the blots were incubated overnight at 4uC with
monoclonal antibodies against proteasome PSMB8 or proteasome
PSMB9, both diluted 1:1000 (Enzo Life Sciences, USA). Staining
was performed with polyclonal rabbit anti mouse immunoglobu-
lins conjugated with horseradish peroxidase (1:1000; Dako,
Denmark) and visualised by enhanced electrochemiluminescence
Pierce ECL Western Blotting Substrate (Thermo Scientific, USA)
(figure 4). For quantification relative to a housekeeping gene, beta
actin was detected using the same procedure and mouse anti-beta
actin diluted 1:10,000 as primary antibody (Sigma, USA).
Quantification on western blot images was performed with the
intensity histogram function of Adobe Photoshop (Munich,
Germany).
Microarray data and statistical analysis
For validation, transcriptome data of muscle biopsies were
collected from the open access database Gene Expression
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/). The selec-
tion included muscle tissue biopsies from different types of IIM,
non-inflammatory myopathies, septic patients, volunteers after IL-
6 infusion and healthy controls as well as purified dendritic cells
from peripheral blood (GSE2044, GSE3112, GSE5370,
GSE39454, GSE3307, GSE13205, GSE10685 and GSE23618;
table S2). Own data included transcriptomes of stimulated
monocytes (GSE38351) [27] and sorted immune cell populations
(CD14+ monocytes, CD15+ granulocytes, CD4+ T-cells, CD8+
T-cells, CD19+ B-cells and CD56+ NK-cells, each n = 3;
GSE58173) from peripheral blood of healthy donors, generated
after RNA extraction, amplification and hybridization to Affyme-
trix GeneChip HG-U133 Plus 2.0 arrays according to standard
protocols to minimize influence on gene expression by sorting
[28]. All data were analysed in the BioRetis database (www.
bioretis.de) using standard algorithms [29]. Selection of differen-
tially expressed genes was performed by ‘‘default increased’’
filtering in BioRetis [29]. Probesets were ranked by an equally
weighted sum-score for ‘‘SLR’’ and ‘‘frequency of increase’’ in
disease compared to control (table S3).
Signals were quantile normalized for evaluation of cell
infiltration and correlation analysis (figure 5). Percentage of
immune cell infiltration was estimated using tissue and cell type
specific marker probesets by comparing the reference transcrip-
tomes of each individual cell type and healthy muscle tissue with
each other (figure 6). To assess the maximum of infiltration related
signal intensity for the immunoproteasome transcripts in each
myositis biopsy a linear model of relationship between signal
intensity and percentage of infiltration was applied. The highest
expected signal (Sexp ) related to infiltration was calculated as
Sexp ~ Smax : Pinf with Pinf as the percentage of all non-muscle
cell types (infiltrated cells) and Smax as the maximum signal
observed in the reference transcriptomes of any of the purified
immune cells from healthy donor. The median of log-transformed
and z-normalized signals of all 1209 myositis related probesets was
used for scoring and sorting of the samples (myositis score).
Results
Dendritic and monocytic cells of the peripheral blood are
the leading cell type for immunoproteasome
upregulation in myositis
Relative quantification of proteasomal subunit expression by
real time RT-PCR revealed a myositis related significant increase
of at least one of the immunoproteasomal subunits PSMB8,
PSMB9 and/or PSMB10 in all investigated cellular subsets except
CD4+ (figure 1). DCs were the leading subset with differences in
all immunoproteasomal subunits followed by monocytes, CD8+
Figure 4. Protein expression of the immunoproteasome subunits PSMB8 and PSMB9 relative to beta actin in IM and NIM. The protein
expression of the two subunits was analyzed by western blot in muscle biopsies from four non-inflammatory myopathies (NIM) and four
inflammatory myopathies (IM). Intensity of chemiluminescent signals for PSMB8 and PSMB9 was normalized to corresponding signals of the
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and finally CD19+ lymphocytes. Differences were most prominent
in PM and to a lower extent in DM patients when compared to
non-inflammatory myopathies (NIM) and healthy donors (HD).
Differences between immunoproteasomal and corresponding
constitutive subunits were especially found between PSMB8 and
PSMB5 in all investigated peripheral blood cell types of all patients
(figure S1) and HD (data not shown).
Immunoproteasomal subunit expression is higher in IIM
than NIM muscle biopsies and indicates a substitution of
constitutive subunits
In all patients with inflammatory myopathies (IM) including
PM, DM and OM, immunoproteasomal subunits PSMB8 and
PSMB9 were significantly increased when compared to NIM
patients (figure 2). In contrast, PSMB10 was less increased in IM
patients compared to NIM and not statistically significant. The
ratios between immunoproteasomal and corresponding constitu-
tive subunits (PSMB8/PSMB5, PSMB9/PSMB6 and PSMB10/
PSMB7) in IM [1.79, 0.35 and 0.42, respectively] compared to
non-inflammatory biopsies [0.94, 0.1 and 0.18, respectively]
indicate an imbalance and suggest substitution of constitutive by
immunoproteasomal subunits in patients with IIM.
Immunoproteasomal subunit expression in IIM is higher
in muscle compared to donor matched immune cells of
peripheral blood
In paired samples of blood and tissue from 7 IM and 6 NIM
patients collected at the same time, real time RT-PCR revealed
significant increase of immunoproteasomal subunits in muscle
compared to blood cells only in IM. In contrast, in NIM,
expression of immunoproteasomal subunits was higher in most
blood cell types compared to muscle tissue (figure 3). Constitutive
subunits were higher expressed in all muscle biopsies from IM and
NIM when compared to any cell type of the blood (data not
shown).
Regulation of PSMB8 and PSMB9 protein in myopathy
patients
To confirm that the elevated transcriptional activity is also
translated into protein, PSMB8 and PSMB9 proteins were
investigated in muscle tissue of representative patients with
Figure 5. Correlation of proteasome subunit expression with myositis signatures and overlap with immune cell infiltration:
Expression of all proteasome units were investigated in transcriptome data of muscle biopsies referenced in table S2 and were correlated with genes
increased in myositis muscle tissue. The heatmap of the probeset signal intensities (A) is opposed to the heatmap of the gene by gene correlation
matrix (B) in 133P array experiments. Identical analysis in 133A arrays are shown in D and E. Expression of the 1209 probesets in reference
transcriptomes of purified immune cells from the blood of healthy donors served as basis for clustering by probesets and cell types (C). Identification
of cell type specific transcriptional patterns in the 1209 probesets demonstrates the extent of overlap of these probesets with immune cell related
transcripts. Myositis samples include IBM (red), PM (orange), DM (yellow), NM (necrotizing myopathy)/IM (inflammatory myopathy) (light green) and
HD (green). Immune cell types include neutrophils (dark blue), monocytes (blue), dendritic cells (light blue), CD4+ T-cells (dark violet), CD8+ T-cells
(violet), NK-cells (light violet), B-cells (cyan), and healthy muscle (moss-green). A detailed graph with all probesets labelled is presented in
supplemental material (figure S4).
doi:10.1371/journal.pone.0104048.g005
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dermatomyositis (P2 and P3), polymyositis (P9), overlap syndrom
(P16) and non-inflammatory muscle diseases (P18, P19, P20, P24).
Western blot analysis revealed equal or higher protein detection
intensities of PSMB8 compared to actin in the patients with
inflammatory muscle diseases and slightly weaker intensities for
PSMB9. In all samples investigated from non-inflammatory
diseases both immunoproteasomal subunits were not visible as a
distinct band (figure 4). Intensities determined for PSMB8/-9
relative to actin were also significantly lower in NIM than in IIM.
Correlation between immunoproteasomal protein and RNA
transcript expression, both as relative quantities compared to
actin protein or transcript, revealed high correlation coefficients of
R = 0.90 for PSMB8 and R = 0.80 for PSMB9.
Transcriptome data for validation and pathophysiologic
classification of defined transcripts
To validate these results and to characterize the importance of
immunoproteasomes in myositis compared to other molecular
mechanisms, we investigated open access transcriptome data of
muscle biopsies from patients with IIM and NIM as well as from
healthy donors. Transcriptomes from different types of immune
cells and stimulation experiments with IFN, TNF and LPS were
selected to address functional interpretation (table S2).
Figure 6. Quantification of cellular infiltration and confirmation of PSMB8/-9 gene activation in myositis muscle samples:
Transcriptome data referenced in table S2 were re-investigated. A) Cell type infiltration was quantified based on the expression of cell specific marker
transcripts (figure S5). Signal ratios between muscle biopsy and purified cell type were calculated for each cell type specific transcriptional markers.
Taking the median of the ratios in each cell specific marker set and scaling their sum to 100% revealed an estimate of the cellular composition.
Increase of monocyte, dendritic cell and T-cell transcription patterns corresponds to the molecular myositis score. (ND = normal donor;
NM = necrotizing myopathy). B) The maximum of infiltration related signal intensity was calculated as described in materials and methods.
Comparing these expected intensities (x-axis) with real intensities (y-axis) in each sample, PSMB8 and PSMB9 are higher expressed than expected in
the majority of IBM and several of the PM muscle. In DM, PSMB8 expression also exceeds the expected signal intensity, although on a lower level. One
out of the 8 DM samples (DM_13) showed consistently a pattern similar to the highly inflamed IBM samples. All other conditions including controls
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Immunoproteasomal subunits PSMB8/-9 are leading
candidates in the pathophysiology of IIM muscle
inflammation. Muscle transcriptomes from patients with
IBM, PM and DM were compared to healthy controls and
revealed 1209 probesets equal to 927 genes, which were
upregulated in at least one of the myositis diseases (table S3) as
a molecular correlate of disease activity. PSMB8 ranked at position
9 and PSMB9 at position 58 out of the 927 genes when scored for
magnitude and consistency of increase. Based on these 1209
probesets, IIM samples did not cluster by disease specific patterns
but overall intensity of molecular changes. High molecular activity
was most frequent in IBM followed by PM and DM muscle
biopsies. This was observed independently for both 133A and
133P data sets (figure 5A, 5E, S2). Of all known proteasomal
subunits, PSMB8/-9 as well as their activator subunits PSME1
and -2 [30] correlated best with the 1209 probesets while most of
the constitutively expressed subunits including PSMB5 and -6
were inversely correlated. This was again independently observed
in 133A and 133P datasets (figure 5B and 5D). Characterizing the
panel of 1209 probesets with DAVID (http://david.abcc.ncifcrf.
gov/) revealed that almost each gene annotated to the antigen
processing and presentation pathways of MHC-I and II was
included (figure S3).
Transcription of PSMB8/-9 is actively up-regulated in
IIM muscle tissue. Investigating gene expression for the 1209
probesets in reference signatures of healthy muscle and immune
cell populations uncovers that the majority is also part of the
physiologic expression in immune cells and is sufficiently specific to
correctly cluster the immune cell profiles (figure 5 C tree of
clustered samples). Thus, these transcripts could be unregulated
but passively transported by cell infiltration into muscle or also
upregulated by additional gene activation (figure 5). Such active
upregulation seems to occur for transcripts specific for healthy
muscle (bottom of figure 5 C), which were increased in myositis. A
magnification of figure 5 with detailed description of genes is
provided in figure S4.
Compared to immune cells, there is no relevant expression of
immunoproteasomes in healthy muscle. Selection of optimized cell
type specific marker transcripts (figure S5) disclosed quantitatively
the cell type specific transcriptional activities in the muscle
biopsies, which were besides muscle especially related to T-cells,
monocytes and dendritic cells and corresponded to the overall
molecular change in myositis muscle transcriptomes (myositis
score; figure 6 A). Comparing real expression levels of immuno-
proteasome subunits in myositis with intensities expected from
immune cell infiltration demonstrated that PSMB8/-9 were
actively upregulated in patients with IBM, PM and DM, especially
when high expression levels not only of the immunoproteasomal
subunits but also of genes differentially expressed in inflammatory
myopathies compared to healthy muscle were observed and thus
were indicative for high molecular disease activity (figure 6 B).
PSMB10 expression, however, matched with expected intensities,
which indicated no additional upregulation.
Transcription factors STAT1 and IRF1 correlate with
upregulation of PSMB-8 and -9 expression in IIM and in IFN
stimulated monocytes. Regulatory mechanisms for immuno-
proteasomes in myositis were searched by correlation of
transcription factors defined by GO:0003700 with PSMB8/-9 in
all muscle biopsy samples. This revealed STAT1, IRF1, TRIM22
and IRF9 as potential regulators, which were predominantly
increased in IBM, but also present in many PM and several DM
samples. PSMB5/-6 were not or inversely correlated. In different
healthy donor immune cell types and healthy muscle, correlation
between PSMB8/-9 and these transcription factors was much
weaker. However, monocytes stimulated with TNF, LPS, IFNa2
or IFNc revealed highest correlation between PSMB8/-9 and
STAT1 followed by IRF1 (table S4). This was related to IFNa2
and IFNc. In contrast, TNF suppressed both transcription factors
and PSMB8/-9, while LPS induced both transcription factors but
suppressed PSMB8/-9 expression (table S4).
In IIM, IFNc but not type-1 IFN correlate with PSMB8/-9
expression and T-cell markers including CD8. Although
both types of interferons may induce PSMB8/-9 [27], in myositis
muscle transcriptomes only IFNc was significantly increased with
dominance in IBM (74% increased change call, 4.9-fold increased)
and correlated with PSMB8/-9. These analyses were separately
performed with 133P and 133A data sets and independently
confirmed each other (figure 7). To trace the cellular origin,
signals of IFNc in myositis were correlated with all cell type
specific marker transcripts and the median of all correlation
coefficients per cell type was calculated. IFNc expression
correlated best with T-cells (133P: R = 0.78; 133A: R = 0.62)
and CD8 (133P: R = 0.80; 133A: R = 0.69) followed by dendritic
cells (133P: R = 0.66; 133P: R = 0.57) in both, 133A and 133P
datasets. NK-cell association was also high in 133P (R = 0.54) but
much lower in 133A datasets (R = 0.17).
Immunoproteasome activation is specific for IIM but not
non-inflammatory myopathies. Reanalysis of muscle tran-
scriptomes from 12 different muscle diseases (GSE3307) with non-
inflammatory myopathies except from juvenile dermatomyositis
(JDM) revealed upregulation of PSMB8/-9 only in samples from
JDM and in one out of four samples from limb girdle muscular
dystrophy 2I (LGMD2I). Furthermore, muscle biopsies from
healthy donors after IL-6 infusion (GSE10685) or patients with
sepsis induced multiple organ failure (GSE13205) did not reveal
any increase of the immunoproteasome expression, indicating that
expression of PSMB8/-9 in muscle is specific for IIM.
Discussion
With this first comprehensive analysis of muscle biopsies and
blood derived immune cells in myositis on the catalytic subunits of
the proteasome, we could demonstrate a central role of
immunoproteasomes in the inflammatory process of IIM including
IBM, PM and DM on transcriptional as well as protein expression
level. We identified PSMB8/-9 upregulation only in combination
with infiltration of antigen presenting cells and associated with the
expression of IFNc and CD8 accompanied by T-cell infiltration in
biopsies of inflamed muscle. This perfectly integrates into current
concepts of IIM pathophysiology and extends these towards a
strong involvement of mechanisms and modulations of antigen
processing.
IIM are of unknown aetiology and present with characteristic
upregulation of MHC-class I and II molecules [1,31], which was
also detectable in the myositis transcriptome data. Antigen
presentation is affected by replacement of constitutive with
immunoproteasomal subunits [13]. In this study, we observed
that physiologic expression of the immunoproteasome subunits in
healthy controls was not only restricted to professional antigen
presenting cells but found in all subtypes of peripheral blood
immune cells. Healthy muscle tissue in contrast expressed only
constitutive subunits while immunoproteasome expression was
negligible. Immunoproteasomal processing is especially linked to
the MHC-I pathway [13]. Thus, it is important that in our
investigation transcription was highly correlated with protein
production of immunopreteasomes and also associated with the
histological finding of MHC-I protein upregulation in muscle
tissue of the analyzed IIM samples.
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Our reanalysis of the myositis transcriptomes revealed that
molecular changes of active inflammation were mainly associated
with an increase of immune cell transcriptome signatures and
interestingly independent from clinical diagnosis. Immunoprotea-
some subunit expression in IIM was upregulated especially in DC
and monocytes of the peripheral blood but also in muscle, where
PSMB8/-9 correlated with the molecular changes of inflammation
and thus infiltration of immune cells. The increase of PSMB8/-9
expression in IIM was higher than the level expected by infiltration
of immune cells and was also higher in total biopsy material with
an immune cells fraction below 40% compared to any of the
purified (100%) donor matched immune cells from peripheral
blood. This clearly indicates that these immunoproteasomal
Figure 7. Correlation of immunoproteasome with IFN and IFNR expression in myositis muscle tissue: Transcriptome data referenced in
table S2 were re-investigated. A) Correlation analysis was performed for 133P and 133A datasets independently. Only IFNc revealed high correlation
coefficients with PSMB8, PSMB9 and PSMB10. The corresponding constitutively expressed subunits PSMB5-7 were not or even negatively correlated.
B) Comparing the association of IFNc with PSMB8, -9 and -10 for each sample individually, the increase was much higher for PSMB8/-9 compared to
PSMB10 as described before (figure 6).
doi:10.1371/journal.pone.0104048.g007
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transcripts must be upregulated in one or more of the cell types of
inflamed muscle.
Recently, transcriptomes obtained from type I and II IFN
stimulated monocytes [27] revealed similar expression patterns of
immunoproteasomal subunits with upregulation of PSMB8/-9 but
not -10, suggesting the involvement of type I and/or type II IFN
triggers on PSMB8/-9 regulation in inflamed muscle tissues. IFNc
was reported to induce MHC-II and enhance MHC-I expression
in affected muscles of PM and DM patients [32]. Recently, an
IFNa signature and influence is discussed especially in DM but
also in PM [33]. In contrast, a role of IFNc triggering is assumed
especially in IBM [34]. In this study, we could identify in the
myositis transcriptomes only IFNc but not IFNa as a predominant
trigger for PSMB8/-9, which also correlated with the expression of
STAT1 and IRF-1. Both transcription factors were also reported
to mediate IFNc induced PSMB9 expression in murine macro-
phages [35]. Interestingly, IFNc production by T-cells was
reported to depend on immunoproteasomes [36]. Especially in
IBM the link of MHC-I with immunoproteasomal units suggests
an important role for antigen processing via PSMB8 and -9
dependent mechanisms. This may be induced by misfolded
protein from fiber degradation or suspected retroviral or viral
triggers in this type of myositis [37] and thereby contribute to
CD8+ T-cell triggering, expansion and IFNc production.
Thus, immunoproteasomes and antigen processing seem to be
pivotal in molecular pathomechanisms of myositis and may serve
particularly as biomarker of myositis activity. This is further
supported by the lack of immunoproteasome activation in our
reanalysis of muscle transcriptomes from non-inflammatory
myopathies [38], patients with severe inflammatory syndroms like
sepsis [39] or conditions related to high IL-6 levels in the
circulation [40].
This important association of immunoproteasome upregulation
with myositis activity raises the discussion, whether these diseases
qualify as a model for therapeutic targeting of immunoprotea-
somes. Inhibitors are currently developed and tested with
controversial effects [41,42]. Application of the PSMB8 selective
inhibitor PR-957 in experimental arthritis or colitis could reduce
cytokine production and attenuate disease activity [43,44]. On the
other hand, the recently described mutations c.224C.T
(p.Thr75Met) [15], G201V [16], G197V [17] and c.405C.A
[18] in PSMB8 were all associated with decreased subunit activity
and different inflammatory syndroms, suggesting that immuno-
proteasome suppression may cause additional effects depending on
dosage and cell type involvement. Studies in PSMB8/-9 deficienct
mice suggested that inflammation induced immunoproteasome
expression in tissue may also prevent CD8+ T-cell mediated
autoimmunity [45].
Knowing that immunoproteasomes modulate antigen process-
ing with effects on MHC-I peptide presentation [46], intracellular
protein homeostasis [47] and CD8 T-cell responses [48] especially
in mixed proteasomes [49], immunoproteasome inhibition may be
a double-edged sword. Influencing antigen processing and
presentation may reduce CD8+ T-cell triggering through MHC-
I but may also increase toxicity by accumulating misfolded
proteins.
In summary, our results support the hypothesis that the
proteasome system is activated and contributes to a perpetuating
crosstalk between antigen-presenting cells and T-cells via im-
munoproteasome generated peptides and IFNc. Assuming altered
autoantigen processing as driving mechanism, suppression of the
immunoproteasome could be a promising therapeutic concept.
Therefore, further studies are needed that focus on antigens and
peptides, which are specifically processed by immunoproteasomes
in IIM as well as on mechanisms of suppressing or modulating
antigen processing and presentation.
Supporting Information
Figure S1 High expression levels of PSMB8 compared to
PSMB5 in all isolated cells: Gene expression of constitutive
(PSMB5-7) and immunoproteasomal subunits (PSMB8-10) in
CD4+, CD8+, CD19+, CD14+, DCs and muscles of all patients.
Data are shown as relative expression normalized to beta actin.
Box plots indicate percentiles 0, 25, 50, 75 and 100.
(TIF)
Figure S2 Differences in upregulation of myositis
related genes between IBM, PM, DM, NM and IM: All
1209 probesets were sorted by a sum-score for magnitude and
frequency of increase in myositis. The heat map presents each
disease group by the mean values of the signal intensity in all
samples of the group. Combined scoring according to analysis on
the 133A and 133P platform demonstrates that the strongest
increase is observed in IBM followed by PM and DM, while IM
and NM were closest to healthy control. This pattern was observed
in 133A samples as well as in 133P samples independently of
combined scoring (A and B) or scoring based on each individual
platform (C and D).
(TIF)
Figure S3 Identification of genes involved in MHC-I and
MHC-II antigen processing and presentation pathways:
The 1209 probesets upregulated in myositis were uploaded into
the DAVID database (http://david.abcc.ncifcrf.gov/) for func-
tional annotation. All genes highlighted with a red star are
included in the 1209 probesets.
(TIF)
Figure S4 This is the corresponding image to figure 5 in
the manuscript. It lists all gene names and is provided as an




Figure S5 Cell type specific transcripts and correspond-
ing changes of gene expression in myositis: Cell type
specific transcripts were determined from transcriptomes of
monocytes, neutrophils, CD1+ dendritic cells, T-cells, B-cells,
NK-cells and muscle tissue by filtering for cell type specific
transcripts with signal level .2000 in the population of interest, ,
200 in all other populations and a fold change of .20 if possible.
In the heatmap on the right side, there is some overlapping
expression in the different types of phagocytic cells and in the
different lymphocyte populations. CD4+ and CD8+ T-cells do not
allow the establishment of a transcript pattern that will distinguish
them from other cell types and at the same time will differentiate
between these two T-cell subpopulations. In the heatmap on the
left side, all myositis transcriptomes were mapped to these marker
panels and samples were sorted by intensity of change in the 1209
‘‘myositis genes’’. This was performed using the median of log-
transformed and z-normalized signals of all 1209 probesets for
each sample as a score (myositis score). Sorting myositis samples
from the lowest score on the left side (predominantly normal donor
samples) to the highest score on the right side (predominantly IBM
samples), there is an increase especially of transcripts related to
monocytes, dendritic cells and T-cells corresponding to the
severity of myositis with a corresponding decrease of muscle
specific transcripts. (Figure S5 is also provided as an additional
separate jpg-file for further magnification: http://www.charite-
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Table S1 Clinical data of patients with DM, PM, OM
and NIM.
(XLS)
Table S2 Collection of transcriptome data from the
Gene Expression Omnibus repository: These transcriptome
data were used for analysis of the role of immunoproteasomes in
inflammatory and non-inflammatory muscle diseases compared to
other genes differentially expressed in myositis.
(XLS)
Table S3 Probesets and genes identified as upregulated
in IBM, PM and/or DM with signal intensities and
molecular scores: Datasets of GSE2044, GSE3112, and
GSE39454 were used to identify molecular changes in IBM, PM
and DM compared to healthy muscle biopsies. Data generated
with the different platforms HG-U133A (133A) and HG-U133Plus
2.0 (133P) were analysed separately to avoid technical bias. Each
disease entity was compared to healthy controls. Selection of
differentially expressed probesets was based on the frequency of
change in pairwise comparisons between arrays from two different
groups, on signal log ratio (SLR), on t-test statistics and on cut-off
for absolute signal intensities combined to a default filtering as
provided in BioRetis. Probesets, which were upregulated in the
same disease in both platforms, were selected and combined from
all diseases to a total of 1209 probesets/927 genes. To score these
probesets by dominance of increase, the frequency of change call
for all pairwise comparisons and the SLR were z-normalized
across all selected probesets and then scaled to the maximum of
‘‘1’’. The sum of both normalized values was used for ranking,
thus identifying genes with the best sum-score for ‘‘highly
increased’’ and ‘‘most frequently increased’’ in disease compared
to control in the top ranks. These probesets were sorted by a sum-
score for magnitude and frequency of increase. See file
‘‘Table_S3.xls’’ accessible via: http://www.charite-bioinformatik.
de/supplementary_data/immunoproteasomes/Tcx8DAP8zJzMD
IKSjY3M_R2cDA3YCQ_nD9_Table_S3.xls. 1. sheet ‘‘probe-
sets’’ with the list of the 1209 probesets sorted by the composed
score of SLR and change call. 2. sheet ‘‘genes’’ with the list of the
927 genes sorted by the composed score of SLR and change call.
3. sheet ‘‘PSM 133P’’ with signals for all proteasomal units of the
133P arrays. 4. sheet ‘‘PSM 133A’’ with signals for all proteasomal
units of the 133A arrays. Data of all microarrys and group
comparisons are available in BioRetis (www.bioretis.com).
(XLS)
Table S4 Correlation of PSMB8 and PSMB9 expression
in myositis with transcriptions factors: Correlation coeffi-
cients on the basis of signal values from myositis muscle biopsies
(columns A1–A4), immune cells (B1–B2) and cytokine stimulated
monocytes (C1–C2) are presented in combination with the z-
normalized signal values of purified immune cells (columns D1–
D21), healthy muscle profiles (E1–E5), cytokine stimulated
monocytes (F1–F22), muscle biopsies based on 133P arrays (G1–
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